Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Tables)

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2020

Schedule of Financial Instrument Measured on Recurring Basis

The valuation methodologies used for the Company’s financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below:

	As of June 30, 2020				Fair Value Measurements
	Carrying		Fair		As of June 30, 2020
	Amount		Value		Level 1		Level 2		Level 3
Liabilities:					(unaudited)
Contingent consideration:
Asuragen ⁽¹⁾	$	2,861	$	2,861	$	-	$	-	$	2,861
Other long-term liabilities:
Warrant liability ⁽²⁾		33		33		-		-		33
	$	2,894	$	2,894	$	-	$	-	$	2,894

	As of December 31, 2019				Fair Value Measurements
	Carrying		Fair		As of December 31, 2019
	Amount		Value		Level 1		Level 2		Level 3

Liabilities:
Contingent consideration:
Asuragen ⁽¹⁾	$	2,893	$	2,893	$	-	$	-	$	2,893
Other long-term liabilities:
Warrant liability ⁽²⁾		82		82		-		-		82
	$	2,975	$	2,975	$	-	$	-	$	2,975

⁽¹⁾⁽²⁾See Note 9, Accrued Expenses and Long-Term Liabilities

Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation

Certain of the Company’s non-financial assets, such as other intangible assets and goodwill, are measured at fair value on a nonrecurring basis when there is an indicator of impairment and recorded at fair value only when an impairment charge is recognized.

								Cancellation		Adjustment
								of Obligation/		to Fair Value/
	December 31, 2019		Payments			Accretion		Conversions Exercises		Mark to Market			June 30, 2020
	(unaudited)
Asuragen	$	2,893	$	(308	)	$	276	$	-	$	-		$	2,861

Underwriters Warrants		82		-			-		-		(49	)		33
	$	2,975	$	(308	)	$	276	$	-	$	(49	)	$	2,894